The Cancer Industry:
The Classic Expose on the Cancer Establishment
New Updated [1996] Edition

© 1996 by Ralph W. Moss, Ph.D.
Published by Equinox Press
(All rights reserved. Please see Copyright notice.)


[WEBSITE NOTE: This is section 4 of the Preface. It concerns some of the underlying problems that exist in alternative cancer medicine, which hinder its acceptance. See also our many Cancer Chronicles articles on the economics of cancer.]

4. Underlying Problems


But all will not be clear sailing. Unfortunately, the fact that the government is finally encouraging a serious study of alternative methods do not render the main conclusions of this book invalid. Before alternative medicine can receive a fair testing, or be accepted, certain major obstacles have to be overcome. The biggest of these, in my opinion, is the entrenched opposition of the "medical-industrial complex."

Monopoly is a long-standing problem. As early as the 1950s and 1960s, five major companies, whom the Federal Trade Commission described as a cartel, were convicted of fixing the prices of then-new antibiotics. Since 1989 there has been an unprecedented wave of mergers: SmithKline and Beecham; Bristol-Myers and Squibb; Glaxo and Wellcome; Pharmacia and Upjohn, etc. In early 1996, Sandoz and Ciba-Geigy announced that they were "rushing into each others' arms" (Wall Street Journal, 3/7/96) to create a giant with a market value of over $60 billion.

Such mega-mergers have turned the pharmaceutical industry "upside down in the past three years" (ibid.). Each of the top ten companies now has annual sales of between six and twelve billion dollars. These mergers raise the specter of even greater monopoly, patent abuse and the stifling of innovation--all things that are disastrous to that spirit of open inquiry in which alternative medicine thrives.

The immediate result of the mergers of the 1990s may be layoffs and other cost-cutting measures, raising their profitability in the short run. But they do not solve the industry's underlying problem, which many analysts identify quite simply as too few good ideas.


The Cancer Industry Introduction:

1. Intro | 2. OTA Study Pt. 1 | 2a. OTA Study Pt. 2 | 3. OAM | 4. Underlying Problems | 5. Role of FDA


Ralph W. Moss, Ph.D. is director of the The Moss Reports for cancer patients. Dr. Moss is the author of eleven books and three documentaries on cancer-related topics. He is or has been an advisor on alternative cancer treatments to the National Institutes of Health, the National Cancer Institute, the American Urological Association, Columbia University, the University of Texas, the Susan G. Komen Foundation and the German Society of Oncology. He wrote the first article on alternative medicine for the Encyclopedia Britannica yearbook. He is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in the East, and Who's Who in Entertainment (as a film documentarian). This Web site does not advocate any particular treatment for cancer. We urge you to always seek competent medical advice for all health problems, especially cancer. Before consulting our site please read our full Disclaimer statement.



home - moss reports - books - - contact - order - news
members - chronicles - faq - free email newsletter